Ownership Submission
FORM 3
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
  Reich Michael
 2. Date of Event Requiring Statement (Month/Day/Year)
03/27/2007		 3. Issuer Name and Ticker or Trading Symbol
Opko Health, Inc. [OPK]
(Last)
(First)
(Middle)
OPKO HEALTH, INC., 4400 BISCAYNE BOULEVARD		 4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
5. If Amendment, Date Original Filed(Month/Day/Year)
03/29/2007
(Street)

MIAMI, FL 33137		 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)		 2. Amount of Securities Beneficially Owned
(Instr. 4)		 3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)		 4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock, $0.01 par value 359,566
D
 
Common Stock, $0.01 par value 194,604
I
See footnote (1)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)		 2. Date Exercisable and Expiration Date
(Month/Day/Year)		 3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)		 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)		 6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Warrant (Right to Buy)   (2) 03/27/2017 Common Stock 10,901 $ 0.6728 D  
Warrant (Right to Buy)   (2) 03/27/2017 Common Stock 10,901 $ 0.8473 D  
Warrant (Right to Buy)   (2) 03/27/2017 Common Stock 10,901 $ 1.0466 D  
Stock Option (Right to Buy)   (3) 12/11/2013 Common Stock 62,273 $ 0.04 D  
Stock Option (Right to Buy)   (3) 11/08/2014 Common Stock 25,947 $ 0.04 D  
Stock Option (Right to Buy)   (3) 02/15/2015 Common Stock 103,788 $ 0.04 D  
Stock Option (Right to Buy)   (4) 02/28/2016 Common Stock 155,682 $ 0.05 D  
Warrant (Right to Buy)   (2) 03/27/2017 Common Stock 5,900 $ 0.6728 I See footnote (5)
Warrant (Right to Buy)   (2) 03/27/2017 Common Stock 5,900 $ 0.8473 I See footnote (5)
Warrant (Right to Buy)   (2) 03/27/2017 Common Stock 5,900 $ 1.0466 I See footnote (5)

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Reich Michael
OPKO HEALTH, INC.
4400 BISCAYNE BOULEVARD
MIAMI, FL 33137		   X      

Signatures

/s/ Kate Inman, Attorney-in-Fact 01/08/2009
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) The 194,604 shares of Common Stock are held by Edonjes LLC, of which Mr. Reich's children are the beneficial owners. Mr. Reich disclaims beneficial interest of the shares of Common Stock held by Edonjes LLC, except to the extent of any pecuniary interest therein.
(2) These warrants are currently exercisable.
(3) These options are fully vested.
(4) 56,219 of these options are fully vested. The balance will vest monthly until fully vested in December 2009.
(5) These warrants of Common Stock are held by Edonjes LLC, of which Mr. Reich's children are the beneficial owners. Mr. Reich disclaims beneficial interest of the warrants to purchase shares of Common Stock held by Edonjes LLC, except to the extent of any pecuniary interest therein.
 
Remarks:
All securities described were acquired in a merger transaction between Acuity Pharmaceuticals, Inc. and eXegenics, Inc.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.